2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 217-219
Technology and Procedures, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Biological Therapies, Antibody Therapy, Transplantation, Infusion, Adverse Events, Biological Processes, Hematopoiesis, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Pediatric
PAPER

874 Efficacy and safety of low-dose decitabine combined with thrombopoietin receptor agonists in refractory severe chemotherapy-induced thrombocytopenia: A retrospective analysis with prognostic factor identification

Bingjie Ding, Fengdi Wang2, Xuewen Song, PhD3, Mengjuan Li4, Junxia Hu5, Hu Zhou, MD6
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Objective: Despite the efficacy of thrombopoietin receptor agonists (TPO-RAs) in milder cancer therapy-induced thrombocytopenia (CTIT), refractory severe cases (grade 4, platelets <25×10?/L) remain an unmet need with no standard therapy, partly due to immune dysregulation and bone marrow (BM) microenvironment damage. Low-dose decitabine, a hypomethylating agent with immunomodulatory and niche-repairing properties, may synergize with TPO-RAs. This study aimed to evaluate the efficacy, safety, and prognostic factors of combining low-dose decitabine with TPO-RAs in refractory severe CTIT.

Methods: This retrospective cohort study included 96 patients with persistent CTIT who received low-dose decitabine (3.5 mg/m²/day ×3 days/cycle, ≥3 cycles) plus a TPO-RA (eltrombopag, hetrombopag, avatrombopag, romiplostim, or rhTPO) between January 2019 and April 2025. Efficacy was assessed at weeks 4, 8, 12, and 24. Response (R) was defined as platelets ≥50×10?/L, significant response (SR) as ≥75×10?/L, and complete response (CR) as ≥100×10?/L, confirmed by two consecutive measurements. Multivariate logistic regression identified predictive factors. Safety was graded by CTCAE v5.0.

Results: The cohort (median age 54.5 years, 52.1% male) had a median baseline platelet count of 9.5×10?/L (range 1–34×10?/L) and a median bone marrow megakaryocyte count of 38 (range 1–885); 79.2% had hypercellular marrow. Remarkably, 97.9% had previously failed TPO-RA monotherapy. The R rates at weeks 4, 8, 12, and 24 were 57.3% (55/96), 73.7% (70/95), 80.0% (76/95), and 83.1% (54/65), respectively; SR rates were 36.5% (35/96), 57.9% (55/95), 64.2% (61/95), and 72.3% (47/65); CR rates were 24.0% (23/96), 38.9% (37/95), 41.1% (39/95), and 35.4% (23/65). Median time to R was 21 days (range 7–147), to SR 35 days (14–147), and to CR 42 days (14–168); median response durations were 140, 126, and 98 days, respectively. Multivariate analysis revealed dynamic predictors: at week 4, baseline platelet count was the strongest factor (OR 1.13–1.29, all P<0.05). At week 8, CD3? T-cell proportion (OR 1.15–1.17), BM megakaryocyte count (OR 1.018–1.04), and number of decitabine cycles (OR 6.17–9.60) independently predicted R and SR (all P<0.05); BM hypercellularity also predicted SR (OR 0.006, P=0.011). By weeks 12 and 24, the number of decitabine cycles became the predominant factor for SR and CR, with ORs up to 86.9 (P=0.022) and 32.3 (P=0.013), respectively, and BM hypercellularity predicted CR at week 24 (OR 0.033, P=0.042). Subgroup analysis showed that patients with BM metastasis had a dismal response (only 12.5% achieved R), whereas no significant efficacy differences were observed among eight different TPO-RA combinations after Bonferroni correction (adjusted α=0.0018), indicating a class effect. Safety was favorable: most adverse events were grade 1–2, including hepatic dysfunction (9.4%), venous thromboembolism (VTE, 8.3%), leukopenia (7.3%), neutropenia (5.2%), and anemia (4.2%). No grade 3–4 myelosuppression, treatment-related discontinuations, or unexpected severe toxicities occurred. The VTE rate remained within the expected cancer background range (4–20%).

Conclusion: Low-dose decitabine combined with TPO-RAs offers robust, rapid, and durable platelet recovery with a favorable safety profile in refractory severe CTIT, even in patients who have failed prior TPO-RA therapy. Baseline platelet count, BM megakaryocyte reserve, T-cell subsets, BM cellularity, and cumulative decitabine cycles serve as valuable prognostic indicators. This combination represents a promising novel strategy and warrants prospective validation.

Bingjie Ding: No relevant conflicts of interest to declare.